Managing Neurocognitive Disorders in the Real World: Optimizing Collaboration Between Primary Care Providers and Dementia Specialists

Evaluating and managing cognitive disorders has become more sophisticated in the last decade with improved imaging, biomarkers, and the introduction of monoclonal antibody therapies for removing amyloid from the brain. Patients with early signs of cognitive loss are generally seen first by primary care physicians who then frequently consult one or more cognitive care subspecialists to obtain an accurate diagnosis and to seek optimized management. This communication serves as an updated review of that collaborative process that now includes decision-making about the suitability for time-critical monoclonal anti-amyloid therapy.